Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
about
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesSystematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitorsCMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studiesSitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes.Extracellular proteases as targets for drug developmentThe DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.Physiology of incretins in health and disease.Advances in the treatment of prediabetes.Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes.Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management.Glucokinase activators in diabetes management.Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.Sitagliptin: a review.Exemplification of the challenges associated with utilising fluorescence intensity based assays in discovery.Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A.Novel DPP-4 inhibitors against diabetes.Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.Food protein-derived bioactive peptides in management of type 2 diabetes.Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.Candidate dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus.Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.Incretin and islet hormonal responses to fat and protein ingestion in healthy men.The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.[Treatment of type 2 diabetes].Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes
P2860
Q24628948-78E7D718-BF27-4CE3-A501-951E054701DDQ26772081-76849577-2C99-41BE-9BCA-7A68857077D4Q33559925-85033391-4F01-4995-9AC3-463BF924DB12Q34569365-EAE44DB1-5EF0-41C3-A266-CA24A1680EC4Q34589793-66A04211-CA00-4EFB-9CB2-27BFC2A8BB84Q34620693-ABC4EDD2-4CB7-49E1-8835-69DFEA5E38D6Q35116202-B907879E-66E0-4AAC-99DF-1E76CB6ACDD3Q35120585-F1213F1B-AF2A-435B-B1D8-43A7DDC999A3Q35760279-1678BA25-2FFA-4C45-B7F7-F5A4C9DB071FQ36327944-6D2B0957-7737-4552-985B-3BFD8E18E466Q36543063-6A504B32-C180-4BBA-9100-6944CEAC5D9BQ36580608-65C43E69-B0C8-4A31-AFCE-D1B0463901C9Q36937820-FF1E6855-BE6A-4D88-97A8-1493A66FE424Q37071183-B10FA2E6-7BA2-4BC0-AD75-6104254A4F4BQ37179450-CB7B17DF-397D-4290-8DC8-05BCEEF8B6F1Q37886184-C86F492F-B827-433B-B180-F59C0ACF009EQ38028561-72FB1D4C-8C6D-4549-81DE-C2375496D82EQ38210234-173962E3-B61F-4D33-8127-A99D2917F79CQ38221278-9F3A220B-0F56-4E50-B8DE-6DC670949436Q38398676-CBBED090-176F-40A7-B342-5192156BC6E8Q38543982-4272EE53-4009-4470-A135-90CBE7E98386Q39205071-F3F990E7-CEED-4467-82F1-99913371184FQ41918134-861FBF2E-DA28-432E-9EFD-932A89221D75Q42575070-C683C178-8042-4D0E-B5CA-9DA4E538326DQ42677651-ADEB5743-D1C5-4CBA-91B1-9FC724FC1362Q42837261-D37CB8DA-07C1-43FB-928E-96768B81CBD3Q43270616-F290FC75-AF72-427D-825C-36A1F9F3373AQ46494673-C23E1B58-5BDE-477B-A981-B61597BC0A8CQ51355945-3DFEA694-ED03-4A32-99E9-DBE85EEC2DEBQ51369410-D47D1F97-E8D8-4EF3-9A26-C7D98D4F1F09Q51376983-A3BEB850-1BFF-478A-B17E-30C22A16E5C0Q51468797-FC830D71-E4DE-4F3D-A222-2CE821ED8F23Q51478119-AADA18E9-85B6-48D6-9890-8911EE354569Q53303236-CD8532F5-23A1-4364-BE29-6916D8583965Q58864225-ABCA916E-0E01-4FD0-A00D-69A984226ECB
P2860
Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Inhibitors of dipeptidyl pepti ...... treatment of Type 2 diabetes?
@ast
Inhibitors of dipeptidyl pepti ...... treatment of Type 2 diabetes?
@en
type
label
Inhibitors of dipeptidyl pepti ...... treatment of Type 2 diabetes?
@ast
Inhibitors of dipeptidyl pepti ...... treatment of Type 2 diabetes?
@en
prefLabel
Inhibitors of dipeptidyl pepti ...... treatment of Type 2 diabetes?
@ast
Inhibitors of dipeptidyl pepti ...... treatment of Type 2 diabetes?
@en
P2860
P50
P1476
Inhibitors of dipeptidyl pepti ...... treatment of Type 2 diabetes?
@en
P2860
P304
P356
10.1517/13543784.13.9.1091
P407
P577
2004-09-01T00:00:00Z